About
Retinal eye-movement tracking for neurological disease (MS, Alzheimer's, Parkinson's, TBI). First 510(k)-cleared device of its kind (May 2023).
HQ: Berkeley, CA, USA
Funding
>$8M raised (Yamaha Motor Ventures, Creative Ventures) + NIH/ADDF grants
Selected for Roche MS Innovation Challenge (Nov 2025).